Literature DB >> 9633992

Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance.

L Fu1, Y C Cheng.   

Abstract

L(-)SddC (3TC) has been shown to be the most promising nucleoside analogue used for the treatment of hepatitis B virus (HBV) infection. Unfortunately, it has been reported that about 12% of HBV-infected patients experience a recurrence of HBV after a period of treatment with 3TC. Point mutations were detected in the HBV polymerase of those viruses from 3TC-resistant patients. A common mutation occurred at methionine in the YMDD motif. In this report, we present mutants that were generated from the HBV genome (adr subtype) by site-directed mutagenesis based on clinical reports from other investigators. With the transient transfection system, it was found that by changing methionine to valine or isoleucine at the YMDD motif, the viral DNA replication would be more than 100-fold less efficient than that of the wild-type virus. Some additional mutations outside the YMDD motif could enhance the replication of the virus containing a YMDD mutation. Various levels of resistance to 3TC were observed in HBV mutants containing point mutations both inside and outside the YMDD motif. These results suggest that the mutations outside the YMDD motif compensate the YMDD mutation to some extent for the viral replication and may also contribute to clinical viral resistance to 3TC.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9633992     DOI: 10.1016/s0006-2952(98)00050-1

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  29 in total

1.  A frequent, naturally occurring mutation (P130T) of human hepatitis B virus core antigen is compensatory for immature secretion phenotype of another frequent variant (I97L).

Authors:  T T Yuan; C Shih
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

2.  Detection of YMDD mutation using mutant-specific primers in chronic hepatitis B patients before and after lamivudine treatment.

Authors:  Cha-Ze Lee; Hsuan-Shu Lee; Guan-Tarn Huang; Pei-Ming Yang; Jin-Chuan Sheu
Journal:  World J Gastroenterol       Date:  2006-09-07       Impact factor: 5.742

3.  Dynamics of hepatitis B virus resistance to lamivudine.

Authors:  Coralie Pallier; Laurent Castéra; Alexandre Soulier; Christophe Hézode; Patrice Nordmann; Daniel Dhumeaux; Jean-Michel Pawlotsky
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

4.  Impact of the rtI187V polymerase substitution of hepatitis B virus on viral replication and antiviral drug susceptibility.

Authors:  Jiyun Fan; Ying Wang; Hui Xiong; Xiaokui Guo; Yung-Chi Cheng
Journal:  J Gen Virol       Date:  2014-07-15       Impact factor: 3.891

5.  In vitro study of the effects of precore and lamivudine-resistant mutations on hepatitis B virus replication.

Authors:  Richard A Heipertz; Thomas G Miller; Colleen M Kelley; William E Delaney; Stephen A Locarnini; Harriet C Isom
Journal:  J Virol       Date:  2007-01-10       Impact factor: 5.103

6.  Mutations outside the YMDD motif in the P protein can also cause DHBV resistant to Lamivudine.

Authors:  Jin-Yang He; Yu-Tong Zhu; Rui-Yi Yang; Li-Ling Feng; Xing-Bo Guo; Feng-Xue Zhang; Hong-Shan Chen
Journal:  World J Gastroenterol       Date:  2005-07-21       Impact factor: 5.742

7.  Hepatitis B virus (HBV) mutations associated with resistance to lamivudine in patients coinfected with HBV and human immunodeficiency virus.

Authors:  V Thibault; Y Benhamou; C Seguret; M Bochet; C Katlama; F Bricaire; P Opolon; T Poynard; H Agut
Journal:  J Clin Microbiol       Date:  1999-09       Impact factor: 5.948

8.  YMDD mutations in patients with chronic hepatitis B untreated with antiviral medicines.

Authors:  Zhong-Min Huang; Qi-Wen Huang; Ya-Qin Qin; Yan-Zhuan He; Hou-Ji Qin; Yiao-Nan Zhou; Xiang Xu; Mei-Jin Huang
Journal:  World J Gastroenterol       Date:  2005-02-14       Impact factor: 5.742

9.  The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance.

Authors:  S K Ono; N Kato; Y Shiratori; J Kato; T Goto; R F Schinazi; F J Carrilho; M Omata
Journal:  J Clin Invest       Date:  2001-02       Impact factor: 14.808

10.  trans-Complementation of HBV rtM204I mutant replication by HBV wild-type polymerase.

Authors:  Richard A Heipertz; Jason L Starkey; Thomas G Miller; Jianming Hu; Harriet C Isom
Journal:  Virology       Date:  2009-04-19       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.